ID   delta-47
AC   CVCL_2887
SY   Delta-47; DELTA-47; Delta 47; DELTA 47; Delta47; DELTA47
DR   Cosmic; 720783
DR   Cosmic; 760400
DR   Cosmic; 2081378
DR   Cosmic; 2302420
DR   Cosmic; 2367274
DR   Cosmic; 2391802
DR   JCRB; JCRB1344
DR   JCRB; NIHS0543
DR   SKY/M-FISH/CGH; 2517
DR   Wikidata; Q54830967
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1329502;
RX   PubMed=8943038;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Population: Japanese.
CC   Characteristics: Produces IgD lambda.
CC   Doubling time: 40 hours (PubMed=1329502).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ5 (CelloPub=CLPUB00604).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0543; true.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): JCRB=JCRB1344
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,11
ST   D5S818: 10,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14,20
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 20
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=1329502; DOI=10.1002/ajh.2830410314;
RA   Ishii K., Yamato K., Kubonishi I., Taguchi H., Ohtsuki Y., Miyoshi I.;
RT   "IgD myeloma presenting as a testicular tumor: establishment and
RT   characterization of an IgD-secreting myeloma cell line.";
RL   Am. J. Hematol. 41:218-224(1992).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P.R., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//